Tel: 561-316-3330
Email: mdnewsmagazine@infomeddnews.com
Home Blog Page 922

SixFix Circular Fixation System Launches

AMDT Holdings, Inc. develops disruptive products to address existing and emerging needs in the extremity market. The clinical use of the SixFix Circular Fixation System began in January, 2020. Initial surgeries were conducted in Tennessee and Ohio with successful surgeries in the treatment of foot and ankle deformities.

The SixFix™ Circular Fixation System is a platform that can address extremity applications in trauma, foot and ankle, and deformity correction for both adults and pediatrics. The SixFix™ System introduces a unique design in which one compact pre-assembled unit of six (6) struts are ready for sterilization and use right out of the box. The strut assembly unfolds to easily connect the rings and eliminates difficult strut exchanges by providing a full range of lengths with a single strut design.

An advanced component of the SixFix™ Circular System is the optional, patented software enabling deformity analysis and correction. A surgeon with two (2) patient radiographs utilizes the unique capabilities of the software to create a prescription that will achieve a corrected deformity and a healed fracture. The SixFix™ software recognizes the six (6) radiopaque fiducial markers that are an integral feature of the SixFix™ fixator with which the software can create an accurate 3D image of the fixator and the deformity. The unique capabilities of the software reduce surgeon input to known values such as ring size and strut length. The software is also able to correct for non-orthogonal radiographs, perspective distortion and variations in radiograph focal point – all of which introduce errors into the common radiograph.

The SixFix™ System will be featured in the Technology Theater (#1769) during the 2020 AAOS Annual Meeting in Orlando on Thursday, March 26th at 9:45 AM. Michael Mullaney, Vice President of Product Development for AMDT Holdings, will present an overview of the disruptive technology within the SixFix™ System software and hardware.

Stephen J. Frania, DPM, FACFAS, a surgeon in Mentor, Ohio, who specializes in reconstructive foot and ankle surgery including lower limb deformity correction, says, “Each strut in the pre-assembled SixFix™ strut assembly is able to extend from 100mm to 300mm. Because I did not have to be concerned about switching out struts intra-operatively as I have with other designs, the application of the frame was fast and easy. At the end of the surgery, I was able to maintain the slim profile of the strut assembly by removing those strut add-ons not required to achieve the final correction.”

Bhekumuzi M. Khumalo, DPM, a foot and ankle surgeon in Union City, TN commented that the SixFix™ Circular Fixation System enabled him to “quickly and easily manipulate the frame to address the deformity by releasing then locking the struts by sliding a locking ring on each strut. This ease of use is important for me since I cannot rely on residents or fellows to lend intra-operative assistance.”

mediQuo an eHealth Startup Closes €2M Funding Round

mediQuo, the leading eHealth app in Spain and Latin America, secured an investment of 2 million euros at the beginning of January 2020, from several renowned investors from the health sector as well as from various Venture Capital investors and Family Offices, with a track record in the digital health space.

All existing investors have joined the round. With the new funding round, which includes all current shareholders, mediQuo can continue its momentum as the leading company in the Spanish medical startup sector.

mediQuo also announces an exciting addition to its management team. Bruno Cuevas will join the company as Co-CEO, along with founder and Co-CEO Dr Guillem Serra. Bruno is the former Vice President of Global Markets at Adevinta/Schibsted, a global group of leading online marketplaces, where he was responsible for an international portfolio of operations in Europe, Asia, Latin America and North Africa. He has also been board member in numerous international marketplaces, including Schibsted Spain (Fotocasa, Infojobs, Milanuncios, coches.net, etc.). Before Adevinta, he worked at Groupon and in strategy consulting.

mediQuo will soon launch its mediQuo PRO app, which will allow doctors and health professionals to manage consultations online for both their own patients as well as for the users of the app. This is in compliance with the European GDPR regulation at all times, thus reinforcing patient and doctor confidentiality. With the launch of mediQuo PRO the company aims to reach a total of 14,000 health professionals and to be able to manage 1.5 million patient consultations within the next 15 months.

mediQuo founder Dr Guillem Serra says: “The recent funding round and the launch of the new app are major boosts to the growth of the platform and to fulfill our purpose to foster the digitization of medicine and healthcare. We are happy to have Bruno Cuevas, joining the team. With his proven track record developing and managing international marketplaces, we are going to take a giant step forward.”

Bruno Cuevas says: “mediQuo wants to change the way in which patients interact with health professionals, thus improving people’s lives. We have a great team, the required technology, knowledge of the health arena as well as of how to operate marketplaces, and the support of renowned investors within the sector. Our ambition is as great as the company’s potential, and with this funding round we have set out to deeply change the health sector – to place a hospital in each person’s pocket.”

This Spanish startup was founded by Guillem Serra, a medical doctor, mathematician, founder and investor in multiple startups, together with Albert Castells and José López, also founders of iSalud.com. Since its launch 2 years ago, mediQuo has received 4 million euros in funding. Its app has been installed by nearly 600,000 users and has been able to manage nearly one million medical consultations, multiplying by 10 the sale of premium subscriptions over the last year.

Novel Device for Continuous Automatic Monitoring of Kidney Function of Hospitalized Patients Introduced

Serenno Medical, a developer of medical devices for patient monitoring in a hospital setting, reveals SentinelTM, a novel, robust device for automatic monitoring and detection of kidney damage in hospitalized patients. The Sentinel device is a continuous urine output monitor that measures urine flow rate and volume in real-time.

Continuous automatic kidney function assessment allows the early detection of Acute Kidney Injury (AKI), a common condition in hospitalized patients that significantly increases the risk of mortality during and after hospitalization. Accurate measurement of urine output (UO) is clinically accepted as the best method for monitoring kidney function. However, UO is currently monitored intermittently and manually by ICU nurses, therefore acute changes in urine flow are difficult to detect. Thus, kidney injury is often detected relatively late, sometimes after it is impossible to prevent further progression.

Sentinel offers a simple and cost-effective solution for the precise, continuous measurement of urine flow rate in real-time. The system promotes early detection of kidney injury, while there is still time to intervene and prevent further damage. It aims to automatically and accurately detect small changes in kidney function, taking the workload off the nursing staff while delivering actionable data. The device works in synergy with existing hospital equipment (any catheter and bag) and requires a short and simple, non-invasive installation. It fits the complicated intensive care unit (ICU) and operating room environments and is fully functional in any patient condition or hospital environment.

Prof. Manu Malbrain, MD, PhD, ICU Director, University Hospital Brussels, Co-founder and Former-President WSACS and Co-founder and President of the International Fluid Academy, said, “Urine output measurement is a key parameter to assess kidney function. However, correct urine output determination is often difficult at the bedside and is usually only performed intermittently and manually. Moreover, the kidneys are often the first organ to stop functioning properly, therefore continuous urine output measurement would be a valuable tool in the management of critically ill, unstable patients.”

Serenno Medical recently completed its first multicenter clinical trial with the Sentinel system, showing high reliability and accuracy in a wide range of environments and patient conditions, including low and high urine flow rates, regardless of patient position, during surgical procedures, and including continuous monitoring of patients in a mobile hospital bed. The clinical trial, conducted at three ICU units in Sheba and Rabin Medical centers in Israel, included more than 40 patients and over 1,300 hours of monitoring. Results show over 96% accuracy and reliability.

“Serenno has developed a unique product that will bring tremendous value to patients hospitalized in ICU units along with a simple digital solution that will bring great economic value to hospitals,” stated Shimon Eckhouse, PhD, Chairman of Serenno Medical. “Serenno’s successful clinical trial is a great testament to the quality and performance of the Company’s product.”

“The successful results of our first clinical trial will allow the company to move forward to manufacturing the device for commercial usage and enable us to bring this best-in-class product to the global medical markets,” said Tomer Lark, Co-Founder and CEO of Serenno Medical. “We expect to receive FDA clearance for the system during 2020 and believe that our patent-pending device has the potential to become the standard-of-care in the OR and ICU, benefiting millions of patients around the world.”

 

SELUTION SLR Sirolimus Drug Eluting Balloon for Endovascular Applications Receives CE Approval: Award Supported by 2 Year Results from the SELUTION SLR First-in-Human Study Involving 50 Patients

SELUTION SLR Sirolimus Drug Eluting Balloon (DEB), for the treatment of peripheral arterial disease has received the CE Mark. This approval applies to sizes from 2.0 x 20mm to 7.0 x 150mm.

This award was supported by two-year results from the SELUTION SLR First-in-Human study, involving 50 patients enrolled across four German centres. SELUTION SLR is the first and only sirolimus drug eluting balloon to have 6 months’ clinical follow-up demonstrating a 2.3% Target Lesion Revascularization (TLR) and a 0.19 Late Lumen Loss (LLL). Two-year clinical results confirmed no deaths or amputations. Patients demonstrated clinical improvement as measured by Rutherford Classification, ABI and walking distance at 6 months and one year, which was maintained out to two years. This evidence demonstrates that a sustained limus release drug eluting balloon is both safe and effective for the treatment of femoropopliteal lesions over a prolonged period.

The study involved 50 patients enrolled across four German centres and achieved excellent freedom from TLR through to two years in 87.5% of subjects, with no primary TLR event observed after Month 11. These figures are low compared to reported historical First-in-Human studies. There were no incidences of death or the need for minor and/or major amputations over this period. These Patients demonstrated clinical improvement as measured by Rutherford Classification, ABI and walking distance at six months and one year, which was maintained out to two years.

“We are very excited to have been awarded our first CE Mark, which is testament to the documented efficacy and safety of our novel sustained limus release eluting balloon”, said MedAlliance Chairman and CEO Jeffrey B. Jump. “We now anticipate that patients in all markets where the CE Mark is recognized will be able to benefit from this breakthrough in drug eluting technology.”

MedAlliance has recently announced completion of its Below The Knee (BTK) First-in-Human study in Singapore. Studies in Arterial Venus Fistula (AVF) and Pedal Arch are to start enrolling soon. A 500 patient post marketing clinical study will follow shortly.

SELUTION SLR Sirolimus Drug Eluting Balloon technology involves unique Micro-Reservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These micro-reservoirs provide controlled and sustained release of the drug. Extended release of sirolimus from stents has been demonstrated highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary CAT™ (Cell Adherent Technology) enables the micro-reservoirs to be coated onto balloons and adhered to the vessel lumen when delivered via an angioplasty balloon.

 

7D Surgical Expands Spine and Cranial Technology Offering

7D Surgical announced today important additions to its cranial and spinal product lines. The company has received both 510(k) clearance from the U.S. Food and Drug Administration (FDA) and a medical device license from Health Canada for its Cranial Biopsy Kit, which allows neurosurgeons to use image guidance to accurately target brain lesions during needle biopsy procedures.

In their effort to support a wide range of surgical instruments, 7D Surgical is also announcing the commercial release of its Universal Tracking Kit which spine surgeons can use to track and visualize almost any rigid surgical instrument on the MvIGS system, including third-party vendor taps and screwdrivers.

“7D Surgical has successfully transitioned from a start-up organization to a growth company, having launched more than 33 MvIGS programs since our full commercial release a little over a year ago. We are very proud of our team for commercializing these latest products in the spine and cranial markets,” said Beau Standish, CEO of 7D Surgical. “2020 will be another break out year for our Machine-Vision innovations and continued North American and international expansion.”

The 7D Surgical MvIGS system utilizes completely new camera-based technology and machine vision algorithms to eliminate the long-standing frustrations with legacy surgical navigational platforms. The system uses only visible light, eliminating the patient and staff exposure to intraoperative radiation which is common with older technologies. This results in a nearly instantaneous patient registration in almost any surgical position.

“We have completed more than 1,500 clinical cases with the 7D Surgical System and the feedback from our surgeon users has been tremendous.  I am excited to offer these new technologies to our customer base which expands the functionality of the MvIGS system while maintaining our clear advantages in speed and reduced radiation exposure to operating room staff and patients,” said Brian Stuart, Vice-President of Sales & Marketing at 7D Surgical.

QYNAPSE Novel Imaging Software for Central Nervous System Diseases Receives FDA Clearance

The news regarding the QyScore® software was announced today by QYNAPSE.

QyScore® provides robust and precise analyses of brain MRI markers that intervene early in the process of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease or multiple sclerosis.

QYNAPSE advises that the software combines an advanced user interface with patient reports that are generated automatically in minutes. The results are presented in comparison to a healthy subject database, supporting neurologists and radiologists in their clinical decision-making. QyScore® is compatible with the clinical routine workflow to support differential diagnosis and measure of clinical progression and also used in clinical trials for monitoring of drug efficacy and safety.

According to Pr. Bruno Dubois, Professor of Neurology at Sorbonne University, and Director of the Memory and Alzheimer’s Disease Institute (IM2A) at Pitié Salpêtrière Hospital in Paris, “QyScore® makes a difference for the diagnosis of dementia at an early stage of the disease when it remains a challenge. The automatic quantification of markers such as brain atrophy, white matter hyperintensities and more, provides highly valuable help to support a timely diagnosis and efficient monitoring of disease progression.”

The software demonstrates its value by quantifying longitudinal changes of regions of interest in the brain, eliminating the inter- and intra-rater variability in images reading, and reducing the time and cost of image analysis notes QYNAPSE.

Commercialization of QyScore® started in Europe following the CE mark approval in September 2017.

“FDA clearance is a major milestone to expand the commercialization of the software within the U.S.,” said Olivier Courrèges, CEO of Qynapse. “Qynapse will accelerate collaboration with experts and healthcare providers in the U.S. to pursue its journey for better patient care in neurology.”

Zynex Obtains European Patent Blood Volume Monitor Device

A European patent has been awarded to Zynex for their blood volume monitor device. The news was announced today. Thomas Sandgaard, the inventor, has assigned the patent to Zynex’s subsidiary, Zynex Monitoring Solutions.

Thomas Sandgaard, CEO said: “I am excited to have obtained European patent protection for the core principles of how we detect fluid imbalances such as excessive blood loss during surgery or internal bleeding in recovery. We received a U.S. Utility Patent protection on the device about a year ago and believe this will strengthen our competitive position in the market for better fluid management in hospitals and surgical centers. This breakthrough technology is unique as there are no other non-invasive devices available that can detect blood loss or internal bleeding.

We believe our non-invasive, easy-to-operate technology will serve an unmet need to manage blood volume in hospital and surgical settings, whether it is fluid loss, fluid overload or internal bleeding which is rarely detected until it becomes critical or fatal. It should be noted, we are still awaiting FDA clearance and European CE marking to fully launch the product into the market.

We believe lives can be saved with this technology as significant complications are avoided during surgery. Fluid management issues can cause organs to malfunction and make recovery more difficult.

Interview with Dr. Dov Rubin, CEO of Lev-El Diagnostics on HeartTrends

MDNM: What is HeartTrends and how can it be used in the early detection of myocardial ischemia?

Dr. Dov Rubin: HeartTrends® is a stress test alternative, offering early detection of myocardial ischemia in relatively healthy individuals without physical stress. The clinically proven test analyzes 20 minutes of heart rate data obtained by wearing a standard heart rate recorder such as a strap, smartwatch or bracelet, without the need for stressful maneuvers or heart strain. This is a true differentiator for those populations for which not having to undertake a stressful test has a meaningful impact – particularly the elderly, impaired and over-weight. HeartTrends’ technology represents the next step in digital heart health monitoring for wearable smart devices – an easy to take, timely and affordable option we would like to see become the newest cardiac risk factor and part of a standard annual health checkup and the normal standard of care.

MDNM: You say HeartTrends is a stress test alternative but without the stress. How easy is HeartTrends really to use?

Dr. Dov Rubin:: There is no physical stress involved in a HeartTrends test. In fact, a user can sit down and record his/her heart rate and HeartTrends will analyse the heart rate variability (HRV) of a normal, non-stressed heart. Sitting, talking, eating, strolling, and even shopping are all acceptable activities that will produce reliable test results. Importantly, this process removes the fear-factor that comes with taking a traditional treadmill stress test and represents an accurate, low-cost, easy-to-use and time-efficient alternative.

MDNM: How does this differ from traditional stress testing?

Dr. Dov Rubin: Both HeartTrends and traditional treadmill stress testing are designed to detect ischemia, but use two different methods to reach a diagnosis. The famous Framingham Heart Study showed that HRV is a well-established marker of mortality and sudden death, which is accentuated in patients with coronary artery disease (CAD) even at rest. Based on this clinical evidence, HeartTrends was developed to provide an innovative analysis with a high sensitivity for early detection of myocardial ischemia at rest.

MDNM: Digital heart health monitoring has been a significant growth area for the wearable smart-device market. Some monitoring devices have failed and/or inefficient. How does HeartTrends differ from similar technology currently being used in the wearable smart devices?

Dr. Dov Rubin:: Today’s wearable smart devices record and calculate all sorts of different statistics, such as the counting of heartbeats in a certain period of time. However, not all of them can create a medically meaningful statement from these statistics. Health monitoring in the wearable smart-device market is moving beyond meaningless statistics and more towards substantial tests that allow individuals to take control of their personal health. HeartTrends is a clinically proven and medically meaningful test relevant to 80% of the world’s healthy population with no known cardiac disease. By comparison, the AFib-detecting technology used in current wearable smart-devices such as The Apple Watch, is only relevant to 2% of individuals. HeartTrends represents a significant upgrade to current technology and has the potential to usher in the next wave in digital heart monitoring for wearable smart device developers.

MDNM: Apple recently released a study in partnership with Stanford University & The American College of Cardiology. Hasn’t The Apple Watch’s AFib feature pre-empted HeartTrends?

Dr. Dov Rubin: Comparing Afib to HeartTrends is like comparing apples to oranges. Afib is not as prevalent in the general population as ischemia. The Apple study on 400,000 individuals, just released this month showed that Afib affected only 0.5% of their population. Comparatively, the Mayo Clinic study using HeartTrends, presented at the American Heart Association, showed the presence of ischemia in 6.3% of healthy individuals. That means HeartTrends is 1,200% more relevant for the general population than monitoring AFib! Notably, a smartwatch with the HeartTrends functionality installed would have the ability to detect ischemia in 80% of the world’s healthy population with no known cardiac disease. Of course, both features in the same smartwatch would create a true digital heart health monitoring powerhouse.

MDNM: What commercial opportunities does this represent for wearable smart-device developers?

Dr. Dov Rubin: Smartwatches can be the hub of true personalized digital health monitoring. To date, some facetiously refer to smartwatches as “solutions seeking real problems to solve.” The first wave of watches measured signals and reported them without interpretation or relevance, such as rudimentary step counting, calorie consumption guesstimates, cumulative heartbeats per day, quality of sleep and more, but fail to provide any meaningful data interpretation behind it. HeartTrends is the new wave of digital health tailor-made for a smartwatch offering the ability to perform an early detection stress test on demand.

MDNM: As a cost-effective, time-efficient and easy to use stress test alternative, what benefits does HeartTrends present to the medical community, particularly for insurers

Dr. Dov Rubin: By offering an early window into the existence of ischemia, insurance companies benefit immediately from improved underwriting via early warning detection of coronary artery disease. The test is both simple and cost effective, allowing more people to be tested than before and radically improving pass through rates of applicants. Just the cost-savings of avoiding a single life insurance policy due to imminent ischemia onset could more than cover the cost of testing the entire population of insurance applicants! “We look forward to recommending HeartTrends to our clients enabling the insurance industry to improve actuarial risk assessment and increase production in the years ahead,” says Hillel Damelin, CEO Swiss Re Israel.

MDNM: HeartTrends received attention when results of the world’s largest prospective multi-center clinical study in collaboration with the Mayo Clinic were announced and presented at The American Heart Association’s (AHA) 2019 Annual Scientific Late Breaking Sessions on November 17th. What was the focus of the study and are future studies planned?

Dr. Dov Rubin: The Mayo Clinic study focused on early detection of ischemia in healthy individuals. This study now introduces the first new cardiac risk factor, HRV, since diabetes was introduced in 1979. People around the world will now have access to take an easy-to-use, and convenient early detection stress test without the fear and apprehension of running on a treadmill to the point of dizziness and fainting. Remember, stress testing is usually reserved only for people who are already suspected of having advanced heart disease. Deploying artificial intelligence and machine learning, as the quantity of tests increase, will enable HeartTrends to grow drastically and refine its ischemia categorizations in the future.

MDNM: How do the findings of the study impact the way we look at traditional cardiac risk factors and what has been the medical community’s reaction?

Dr. Dov Rubin: The medical community has already expressed interest about this new, easy-to-use, and cost-effective analysis as it offers a unique window into the individual’s heart health. University of Rochester Professor and Director of Cardiology, Ilan Goldenberg MD, said it best, “In the era of wearable digital monitoring devices and increased interest in personalized approaches to risk assessment, HRV will provide useful information to direct lifestyle change, and to monitor general health status.”

MDNM: We are seeing so many changes and trends in the way we detect various diseases and other health issues. Do you believe we are at a tipping point for the democratization of personal health care and how does HeartTrends fit in with this?

Dr. Dov Rubin:: This is an exciting time – in the evolution of wearable technologies – and, equally, for people to now have the access to the information necessary to take control over their personal health. The challenge is finding a way to scale such advancements in medical technology so that people worldwide have access to, and can benefit from, them. With heart rate monitoring now a ubiquitous measurement, HeartTrends offers the ability to elevate these measurements and obtain insights to heart-health at a globally affordable price point – the democratization of health monitoring.

MDNM: What are the next steps for Lev El Diagnostics and HeartTrends in this space?

Lev-EL Diagnostics – the developers of HeartTrends – is continuing its research into other diseases that affect the autonomic nervous system reflected by measuring HRV. We are currently undertaking advanced international research into early detection of diabetes – a world epidemic – as well as contemplating early detection of Parkinson’s disease.

MDNM: How easy is it for consumers to access HeartTrends technology?

Dr. Dov Rubin:: HeartTrends is currently a B2B product administered by health clinics and labs around the world. The test is medically CE-certified across Europe and has performed over 24,000 tests. The app is available by simple download from the Google Play Store outside the US. It will soon be available in the US and for Apple users as well. We are seeking discussions with smartwatch manufacturers to make HeartTrends available to the general public as a B2C feature adding significant value to each device. This has the real potential to be a smartwatch game-changer.

MDNM: Lastly, how can people learn more about HeartTrends?

Dr. Dov Rubin: More information can be found on the HeartTrends’ website (www.heartrends.com) or by contacting info@Levhm.com.

 

Perfect AAA EVAR Stent Has Not Been Designed or Produced: All Current AAA EVAR Devices are Obsolete

This debate has been ignited by the publication of draft guidelines by the National Institute for Health and care Excellence (NIcE) in the UK, which recommend against Endovascular aortic repair (EVAR) as the first line management of elective infrarenal aortic aneurysm, largely on the grounds of high re-intervention rates and cost-effectiveness.

Draft NICE guidelines have sent major ripples through the community of surgeons and interventionalists who treat these patients, but yet they have also provided an opportunity for reflection and that forms the basis for this review. EVAR and open surgical repair are not competitive therapies, each has its merits and a patient specific approach should be taken when deciding on the appropriate method for each individual patient.

Endovascular repair still has a major role to play in modern practice, in good clinical indication and will continue to do so for years to come, with the caveat that contemporary devices are not perfect and there is room for improvement. In this review a comprehensive overview of the commercially available devices is presented, which includes various clinical, biomechanical and biological considerations.

Our latest publications on AAA EVAR Stent had shown that the Perfect Stent Had Not Been Designed or Produced and all current AAA devices are obsolete.

All Multinationals Have Focused on Reducing Profile of Delivery System in Order to Make Technology More Amenable to Percutaneous Access Thereby Expanding Customer Base to Interventional Cardiologists. In Their Pursuit of Market Share, they Compromised Fundamental Science Behind Design of a Good Endograft & Jeopardised Long-term Durability.

The optimum graft must have Proximal & Distal Fixation by Stainless Steel build Stents Without Any Barbs. Barbs induces a systemic and local inflammatory process that leads to expansion of the aortic neck. All Endograft Must Have an Exoskeleton Covered with An Ultra-thin Layer of ePTFE to protect the main graft. The Main Body Must have a Ringed Stents Rather Than Z Stents to allow elastic recoil and prevent cardiovascular major adverse clinical events mainly systolic hypertension and congestive heart failure.

Iliac Flared Limbs More Than 24mm In Diameter Should Be Avoided as Larger Iliac Diameters Induce Major Pulsation Forces & Distort Blood Flow from Main Graft Body.

Moreover, any available graft on the market, where the Main body of the graft and its iliac limbs with is 14 mm in diameter or less must be abandoned as it predisposes to thromboses in any event of hypotension. Polyester grafts had the highest incidence of limb thrombosis which over take the advantage of less type II endoleak.

A high-volume centers personalized patient approach to every patient with aortic aneurysm must be adopted. Vascular surgeons alone provide both open repair and EVAR treatments without the need for any interventional radiology team, as it is mandatory in UK Centers. To increase applicability of EVAR, over the broad spectrum of aorto-iliac anatomic configurations, vascular surgeons must master at least 4 grafts.

Investigational FEVAR Or BEVAR must nnly be executed during a course of a clinical trial with a sturdy safety committee that can collapse the program when such ploys show harm, toxicity and maltreatment to the patients.

A patient is better served with straight EVAR or alternatively open repair. Fixing the aorta at four points, two at the renals arteries and two at the mesenteric branches are invitation for a catastrophe, with risks of critical shuttering and loss of native side branches in 50% of patients.

More over a metallic jacket acting as a long stiff tube in the aorta causes a negative haemodynamic cardiovascular consequence which had been ignored. All such cases develop congestive cardiac failure, systolic hypertension and succumb to cardiac complications. We substituted aneurysm related mortality with cardiac related mortality

All vascular surgeons must shortened the aorta stented segment in order to decrease the negative cardiovascular consequences.

Giant AAA must be mastered by open surgical repair in high volume centers.

AAA must be repaired on a smaller diameter with precision designed grafts to ensemble patients from oversizing with minimum numbers of modular or limbs components.

Vascular surgeons must master the lost art of open complex aortic surgery.

Dr. Sherif Sultan’s published paper in the Italian Journal of Vascular and Endovascular Surgery can be found here.

The Hip Hook: Releases Unresolved Pain by Simply Laying on It

The Hip Hook: After decades of practice as a physical therapist, Christine Koth saw a pattern emerge.

Nearly everyone had a tight iliacus muscle and next to no one was aware of it. In her practice, this pattern of tightness soon became a predictable root cause of pain in the lower back, hip, tailbone, knee, and foot.

After countless successes releasing the iliacus with her hands and no effective tools on the market for people to release it themselves, Christine was compelled to create the Hip Hook, the only tool that can replicate the iliacus muscle release that only a skilled practitioner could previously provide. By simply lying upon the Hip Hook for 2 minutes per day, tension in this muscle dissolves for good.

“A tight iliacus is a missing link in recovery from back, tailbone, hip, and knee pain since it affects the alignment of the entire body. Get Hip Hooked and experience the ‘hurts so good’ release of the muscle that you didn’t know was tight.” – Christine Koth, Inventor

The Hip Hook pre-sale officially starts today with big discounts and perks here.

Christine Koth, MPT is a physical therapist who has specialized in the hip area for decades and has been aptly named the “Iliacus Queen.” She recently put the iliacus muscle on the map in her best-selling book, Tight Hip, Twisted Core – The Key to Unresolved Pain, where she uncovers the 3 major causes of a tight iliacus:

  • Too much sitting or driving
  • Overuse with activities like running, cycling, and kicking
  • Hyperflexibility, yoga, and dance

When tension in the iliacus remains unchecked, it compresses the hip and twists the core, changing the mechanics of the pelvis, spine, and hip in a way that can contribute to pain all over the body. For many, the Hip Hook is the missing link to enjoying a pain-free life. With over $30,000 sold on the first day of pre-sale, the Hip Hook is making its mark in the wellness scene. More on this here.

1...921922923Page 922 of 923

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330